Physician profile
Karen Silver
NPI 1598806002
$1,187.53
in general payments reported to CMS, 2019-2025
9 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Primary Podiatric Medicine provider received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $37.12 · 2021: $125 · 2022: $203 · 2023: $222 · 2024: $46.34 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $533.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $696.81 | 2019-2025 | Jublia |
| Globus Medical, INC. | $170.31 | 2025 | Senza |
| Sebela Pharmaceuticals INC. | $162.34 | 2020-2023 | Naftin, Pramosone |
| Abbott Laboratories | $34.02 | 2019 | |
| Paratek Pharmaceuticals, INC. | $33.72 | 2023 | Nuzyra |
| Grt US Holding, INC. | $29.99 | 2022 | |
| Zyla Life Sciences, INC. | $24.38 | 2019 | |
| Alfasigma USA, INC. | $21.96 | 2021 | |
| Glenmark Therapeutics INC. | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.